Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, announced a strategic shift to prioritize the development of its clinical-stage oncology programs. The company will concentrate on advancing its key programs—lunresertib, camonsertib, RP-1664, and RP-3467—while significantly reducing its preclinical research efforts.
“We are redirecting our resources to our most promising oncology programs to maximize value for patients and shareholders,” said Lloyd M. Segal, President and CEO of Repare. “We remain on track to report data from our MYTHIC dose expansion trial evaluating lunresertib with camonsertib for ovarian and endometrial cancers in Q4 2024, with potential for a registrational trial in 2025.”
As part of this strategic realignment, Repare plans to reduce its workforce by about 25%, mainly from the preclinical team, resulting in one-time costs of $1.5-$2.0 million and annual savings of approximately $15 million, extending its cash runway into the second half of 2026.
Clinical Programs and Key Milestones:
- Lunresertib (RP-6306): A first-in-class PKMYT1 inhibitor, currently in the MYTHIC trial for platinum-resistant ovarian and endometrial cancers. Data is expected in Q4 2024, with potential to start a registrational trial in 2025. Additional studies are ongoing with Debio 0123 and in the MINOTAUR trial with FOLFIRI.
- Camonsertib (RP-3500): A potential best-in-class ATR inhibitor, under evaluation as a monotherapy in the Phase 2 TRESR trial for ATM-mutated non-small cell lung cancer (NSCLC). Initial data is expected in 2025.
- RP-1664: A highly selective PLK4 inhibitor in a Phase 1 trial (LIONS) for TRIM37-high solid tumors, with plans to advance into a Phase 1/2 trial for high-risk, recurrent pediatric neuroblastoma.
- RP-3467: A Polθ ATPase inhibitor with plans to initiate a Phase 1 dose-finding trial in Q4 2024.
About Repare Therapeutics:
Repare Therapeutics is a precision oncology company using a synthetic lethality approach and its SNIPRx® platform to develop targeted cancer therapies. The company’s pipeline includes multiple clinical and preclinical programs aimed at exploiting genomic instability in cancer.
